Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk

On August 20, 2020, the United States (US) Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) along with a label update to inform the public about a small increased risk of non-melanoma skin cancer associated with hydrochlorothiazide (HCTZ) use. The DSC advised that patients continue HCTZ use and take protective measures for skin cancer, unless otherwise instructed by healthcare providers.

This presentation evaluated the impact of this DSC and label update on HCTZ use METHODS: We conducted trend analyses using claims data in the Sentinel Distributed Database and MerativeTM MarketScan® Research Databases from January 2017 to November 2022. It was presented at the 2024 ISPE Annual Meeting.